Details
|
AVI BioPharma, inc., is a biopharmaceutical industry which is focusing on therapeutics products indicated for the treatments of the life-threatening disorders using 3d generation NEUGENE antisense medications. Company's primary drugs indicated for the treatment of such life threatening disorders as cancer, infectious disease, and cardiovascular disease. Company's main product candidate is a NEUGENE antisense medication, called Resten-NG, which is indicated to treat cardiovascular restenosis, as well for the narrowing of a coronary arteries followed angioplasty. Additionally, for targeting certain body's genes, Avi’s biopharmaceutical company's antiviral programs use NEUGENE antisense agents to combat diseases by direct targeting single-stranded RNA viruses, such as Ebola Virus, Dengue Virus, Hepatitis C Virus, and West Nile virus. AVI is also evaluating a therapeutic cancer vaccine called Avicine in 6 clinical studies involving pancreatic and colorectal cancers; evaluating phase 1 studies of AVI 4126 , targeting polycystic kidneys disorders; and completing phase IB/2 studies of AVI 4557 targeting drugs metabolism. Avi is collaborating with Exelixis,inc; Medtronic,inc; and SuperGen,inc. AVI Biopharma,inc. was discovered in 1980 under the name Antivirals,inc; and changed the name to AVI BioPharma,inc. in 1998. The company is headquartered in Portland, Oregon. Visit: www.antivirals.com for more information. Or Tel 503-227-0554. (Nasdaq Symbol: VII)
|
